ENTA
Enanta Pharmaceuticals Inc.
$7.70
+$0.06(+0.79%)
36
Overall
--
Value
36
Tech
--
Quality
Market Cap
$163.33M
Volume
193.48K
52W Range
$4.09 - $13.37
Target Price
$16.33
Order:
Income Statement
| Metric | Trend | Chart | 2015 Sep | 2016 Sep | 2017 Sep | 2018 Sep | 2019 Sep | 2020 Sep | 2021 Sep | 2022 Sep | 2023 Sep | 2024 Sep |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $160.9M | $88.3M | $102.8M | $206.6M | $205.2M | $122.5M | $97.1M | $86.2M | $79.2M | $67.6M | ||
| Total Revenue | $160.9M | $88.3M | $102.8M | $206.6M | $205.2M | $122.5M | $97.1M | $86.2M | $79.2M | $67.6M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $-200.0K | -- | $-78.2M | $-118.3M | $168.5M | $-164.1M | -- | -- | -- | -- | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $160.9M | $88.3M | $102.8M | $206.6M | $205.2M | $122.5M | $97.1M | $86.2M | $79.2M | $67.6M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $36.7M | $57.4M | $78.2M | $118.3M | $168.5M | $164.1M | $206.6M | $210.0M | $216.4M | $189.3M | ||
| Research & Development | $23.2M | $40.5M | $57.5M | $94.9M | $142.2M | $136.8M | $174.1M | $164.5M | $163.5M | $131.5M | ||
| Research Expense | $23.2M | $40.5M | $57.5M | $94.9M | $142.2M | $136.8M | $174.1M | $164.5M | $163.5M | $131.5M | ||
| Selling, General & Administrative | $13.5M | $17.0M | $20.7M | $23.4M | $26.2M | $27.4M | $32.5M | $45.5M | $52.9M | $57.9M | ||
| General & Administrative Expenses | $13.5M | $17.0M | $20.7M | $23.4M | $26.2M | $27.4M | $32.5M | $45.5M | $52.9M | $57.9M | ||
| Salaries & Wages | $-5.8M | $-9.4M | $-13.1M | $-15.8M | $-19.2M | $-19.6M | -- | -- | $28.2M | $26.8M | ||
| Depreciation & Amortization | $-639.0K | $-1.7M | $-2.1M | $-2.5M | $3.3M | $3.6M | $3.3M | $3.0M | $2.4M | $2.3M | ||
| Depreciation & Amortization | $-639.0K | $-1.7M | $-2.1M | $-2.5M | $-3.3M | $-3.6M | $3.3M | $3.0M | $2.4M | $2.3M | ||
| Other Operating Expenses | $-324.0K | $-294.0K | $-134.0K | $-563.0K | $-156.0K | $-11.0K | $-10.0K | $-10.0K | $-882.0K | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $124.1M | $30.8M | $24.6M | $88.3M | $36.7M | $-41.6M | $-109.6M | $-123.8M | $-137.2M | $-121.7M | ||
| EBITDA | $128.3M | $35.8M | $29.8M | $94.8M | $44.5M | $-38.0M | $-104.2M | $-119.2M | $-128.6M | $-115.5M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $8.0K | $45.0K | $40.0K | -- | -- | -- | -- | -- | $5.1M | -- | ||
| Intinc | $968.0K | $1.7M | $2.5M | $4.9M | $8.8M | $6.5M | $2.0M | $1.6M | $11.4M | -- | ||
| Net Non-Operating Interest Income/Expense | $960.0K | $1.7M | $2.5M | $4.9M | $8.8M | $6.5M | $2.0M | $1.6M | $6.2M | -- | ||
| Gain on Sale of Securities | $347.0K | $29.0K | $-159.0K | $-59.0K | -- | $149.0K | $-27.0K | -- | $11.4M | $14.8M | ||
| Other Income/Expense | $-347.0K | $-29.0K | $159.0K | $59.0K | $-9.3M | $-149.0K | $27.0K | $83.0K | $-11.4M | $-14.8M | ||
| Other Special Charges | $509.0K | $471.0K | $660.0K | -- | $9.3M | -- | $-27.0K | $83.0K | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $125.5M | $32.6M | $26.9M | $93.1M | $45.6M | $-41.6M | $-107.6M | $-122.2M | $-131.0M | $-117.8M | ||
| Pre-Tax Income | $125.5M | $32.6M | $26.9M | $93.1M | $45.6M | $-35.0M | $-107.6M | $-122.2M | $-131.0M | $-117.8M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $46.5M | $10.9M | $9.2M | $21.2M | $-826.0K | $1.1M | $-28.6M | $-433.0K | $2.8M | $-1.7M | ||
| NET INCOME | ||||||||||||
| Net Income | $79.0M | $21.7M | $17.7M | $72.0M | $46.4M | $-36.2M | $-79.0M | $-121.8M | $-133.8M | $-116.0M | ||
| Net Income (Continuing Operations) | $79.0M | $21.7M | $17.7M | $72.0M | $46.4M | $-36.2M | $-79.0M | $-121.8M | $-133.8M | $-116.0M | ||
| Net Income (Discontinued Operations) | $79.0M | $21.7M | $17.7M | $72.0M | $46.4M | $-36.2M | $-79.0M | $-121.8M | $-133.8M | $-116.0M | ||
| Net Income (Common Stockholders) | $79.0M | $21.7M | $17.7M | $72.0M | $46.4M | $-36.2M | $-79.0M | $-121.8M | $-133.8M | $-116.0M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-119.5M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-36.9M | $57.4M | -- | -- | $336.9M | -- | $206.6M | $210.0M | $216.4M | $189.3M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $18.7K | $18.9M | $19.1M | $19.3M | $19.6M | $19.9M | $20.2M | $20.6K | $21.0K | $21.2K | ||
| Average Shares Outstanding (Diluted) | $19.3K | $19.2M | $19.4M | $20.6M | $21.0M | $19.9M | $20.2M | $20.6K | $21.0K | $21.2K | ||
| Shares Outstanding | $18.8M | $19.0M | $19.1M | $19.4M | $19.7M | $20.1M | $20.3M | $20.8M | $21.1M | $21.2M | ||
| Basic EPS | $4.23 | $1.14 | $0.93 | $3.74 | $2.37 | $-1.81 | $-3.92 | $-5.91 | $-6.38 | $-5.48 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | $-3.92 | $-5.91 | $-6.38 | $-5.48 | ||
| Diluted EPS | $4.09 | $1.13 | $0.91 | $3.48 | $2.21 | $-1.81 | $-3.92 | $-5.91 | $-6.38 | $-5.48 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | $-3.92 | $-5.91 | $-6.38 | $-5.48 | ||
| OTHER METRICS | ||||||||||||
| Gain On Sale Of P P E | $31.0K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Net Income Discontinuous Operations | $518.0K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $13.5M | $17.0M | $20.7M | $23.4M | $26.2M | $27.4M | $32.5M | $45.5M | $52.9M | $57.9M | ||
| Provision For Gain Loss On Disposal | $518.0K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $13.5M | $17.0M | $20.7M | $23.4M | $26.2M | $27.4M | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ENTA | $7.70 | +0.8% | 193.48K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Enanta Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW